X4 Pharma's Mavorixafor Gets Positive CHMP Opinion for WHIM Syndrome Treatment

X4 Pharmaceuticals' mavorixafor has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the treatment of WHIM syndrome, a rare congenital immunodeficiency disorder. A decision from the European Commission is expected in Q2 2026. The positive opinion was based on results from a Phase 3 trial. Norgine will commercialize mavorixafor in Europe, Australia, and New Zealand under a licensing and supply agreement.